Archer, RP. Fluoromethcathinone, a new substance of abuse. Forensic Sci. Int., 1 Jan 2009, 185 (1–3), 10–20. 1.4 MB. https://doi.org/10.1016/j.forsciint.2008.11.013 #3 GC,MS,NMR,IR
Camilleri, A; Johnston, MR; Brennan, M; Davis, S; Caldicott, DGE. Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluoromethamphetamine, α-phthalimidopropiophenone and N-ethylcathinone. Forensic Sci. Int., 15 Apr 2010, 197 (1), 59-66. 736 kB. https://doi.org/10.1016/j.forsciint.2009.12.048 MS,NMR,IR
Iversen, LL. Consideration of the cathinones, Advisory Council on the Misuse of Drugs, 31 Mar 2010. 286 kB.
Maheux, CR; Copeland, CR; Pollard, MM. Characterization of three methcathinone analogs: 4-methylmethcathinone, methylone, and bk-MBDB. Microgram J., 1 Dec 2010, 7 (2), 43–49. 765 kB. #2c MS,NMR,IR,other
Angoa-Pérez, M; Kane, MJ; Francescutti, DM; Sykes, KE; Shah, MM; Mohammed, AM; Thomas, DM; Kuhn, DM. Mephedrone, an abused psychoactive component of ‘bath salts’ and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J. Neurochem., 1 Mar 2012, 120 (6), 1097–1107. 777 kB. https://doi.org/10.1111/j.1471-4159.2011.07632.x
Baumann, MH; Ayestas, MA; Partilla, JS; Sink, JR; Shulgin, AT; Daley, PF; Brandt, SD; Rothman, RB; Ruoho, AE; Cozzi, NV. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacol., 1 Apr 2012, 37, 1192–1203. 763 kB. https://doi.org/10.1038/npp.2011.304
Santali, EY; Cadogan, A; Daeid, NN; Savage, KA; Sutcliffe, OB. Synthesis, full chemical characterisation and development of validated methods for the quantification of (±)-4′-methylmethcathinone (mephedrone): a new “legal high”. J. Pharm. Biomed. Anal., 10 Sep 2011, 56 (2), 246–255. 705 kB. https://doi.org/10.1016/j.jpba.2011.05.022 GC,LC,MS,NMR,IR,UV
Brandt, SD; Sumnall, HR; Measham, F; Cole, JC. Analyses of second-generation ‘legal highs’ in the UK: Initial findings. Drug Test. Anal., 1 Aug 2010, 2 (8), 377–382. 317 kB. https://doi.org/10.1002/dta.155 #2 MS,NMR
Jankovics, P; Váradi, A; Tõlgyesi, L; Lohner, S; Németh-Palotás, J; Kőszegi-Szalai, H. Identification and characterization of the new designer drug 4′-methylethcathinone (4-MEC) and elaboration of a novel liquid chromatography-tandem mass spectrometry (LC-MS/MS) screening method for seven different methcathinone analogs. Forensic Sci. Int., 15 Jul 2011, 210 (1–3), 213–220. 899 kB. https://doi.org/10.1016/j.forsciint.2011.03.019 #1 MS,NMR,IR,UV
Power, JD; McGlynn, P; Clarke, K; McDermott, S; Kavanagh, PV; O’Brien, J. The analysis of substituted cathinones. Part 1: Chemical analysis of 2-, 3-, and 4-methylmethcathinone. Forensic Sci. Int., 10 Oct 2011, 212 (1–3), 6–12. 1.1 MB. https://doi.org/10.1016/j.forsciint.2011.04.020 GC,MS,NMR,IR
Tsujikawa, K; Mikuma, T; Kuwayama, K; Miyaguchi, H; Kanamori, T; Iwata, YT; Inoue, H. Degradation pathways of 4-methylmethcathinone in alkaline solution and stability of methcathinone analogs in various pH solutions. Forensic Sci. Int., 10 Jul 2012, 220 (1–3), 103–110. 671 kB. https://doi.org/10.1016/j.forsciint.2012.02.005
Elie, L; Baron, M; Croxton, R; Elie, M. Microcrystalline identification of selected designer drugs. Forensic Sci. Int., 10 Jan 2012, 214 (1–3), 182-188. 1.4 MB. https://doi.org/10.1016/j.forsciint.2011.08.005
Brunt, TM; Poortman, A; Niesink, RJM; van den Brink, W. Instability of the ecstasy market and a new kid on the block: mephedrone. J. Psychopharmacol., 1 Nov 2011, 25 (11), 1543–1547. 238 kB. https://doi.org/10.1177/0269881110378370
Dargan, PI; Sedefov, R; Gallegos, A; Wood, DM. The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Test. Anal., 1 Jul 2011, 3 (7–8), 454–463. 149 kB. https://doi.org/10.1002/dta.312
Wood, DM; Dargan, PI. Mephedrone (4-methylmethcathinone): What is new in our understanding of its use and toxicity. Prog. Neuro-Psychopharmacol. Biol. Psych., 3 Dec 2012, 39 (2), 227-233. 251 kB. https://doi.org/10.1016/j.pnpbp.2012.04.020
Toole, KE; Fu, S; Shimmon, RG; Kraymen, M; Taflaga, S. Color tests for the preliminary identification of methcathinone and analogues of methcathinone. Microgram J., 1 Jan 2012, 9 (1), 27–32. 496 kB.
McDermott, SD; Power, JD; Kavanagh, PV; O’Brien, J. The analysis of substituted cathinones. Part 2: An investigation into the phenylacetone based isomers of 4-methylmethcathinone and N-ethylcathinone. Forensic Sci. Int., 10 Oct 2011, 212 (1–3), 13–21. 1.1 MB. https://doi.org/10.1016/j.forsciint.2011.06.030 #2a GC,MS,NMR,IR
Khreit, OIG; Grant, MH; Zhang, T; Henderson, C; Watson, DG; Sutcliffe, OB. Elucidation of the Phase I and Phase II metabolic pathways of (±)-4′-methylmethcathinone (4-MMC) and (±)-4′-(trifluoromethyl)methcathinone (4-TFMMC) in rat liver hepatocytes using LC–MS and LC–MS2. J. Pharm. Biomed. Anal., 18 Jan 2013, 72, 177–185. 800 kB. https://doi.org/10.1016/j.jpba.2012.08.015 #3a GC,LC,MS,NMR,IR,UV,other
Zuba, D. Identification of cathinones and other active components of ‘legal highs’ by mass spectrometric methods. Trends Anal. Chem., 1 Feb 2012, 32, 15–30. 576 kB. https://doi.org/10.1016/j.trac.2011.09.009
Morris, K. UK places generic ban on mephedrone drug family. Lancet, 17 Apr 2010, 375 (9723), 1333–1334. 52 kB. https://doi.org/10.1016/S0140-6736(10)60559-4
Spiller, HA; Ryan, ML; Weston, RG; Jansen, J. Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clin. Toxicol., 1 Jul 2011, 49 (6), 499–505. 130 kB. https://doi.org/10.3109/15563650.2011.590812
EMCDDA. Report on the risk assessment of mephedrone, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, . 2.2 MB. #Mephedrone
Reitzel, LA; Dalsgaard, PW; Müller, IB; Cornett, C. Identification of ten new designer drugs by GC-MS, UPLC-QTOF-MS, and NMR as part of a police investigation of a Danish Internet company. Drug Test. Anal., 1 May 2012, 4 (5), 342–354. 1.2 MB. https://doi.org/10.1002/dta.358 #Mephedrone GC,LC,MS,NMR
Zuba, D; Byrska, B. Prevalence and co-existence of active components of ‘legal highs’. Drug Test. Anal., 1 Jun 2013, 5 (6), 420–429. 1.3 MB. https://doi.org/10.1002/dta.1365
Kanu, AB; Brandt, SD; Williams, MD; Zhang, N; Hill, HH. Analysis of psychoactive cathinones and tryptamines by electrospray ionization atmospheric pressure ion mobility time-of-flight mass spectrometry. Anal. Chem., 17 Sep 2013, 85 (18), 8535–8542. 1.6 MB. https://doi.org/10.1021/ac401951a
Cameron, K; Kolanos, R; Vekariya, R; De Felice, L; Glennon, RA. Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of “bath salts,” produce opposite effects at the human dopamine transporter. Psychopharmacology, 1 Jun 2013, 227 (3), 493–499. 190 kB. https://doi.org/10.1007/s00213-013-2967-2
Westphal, F; Junge, T; Rõsner, P; Girreser, U; Fritsch, R. Massenspektrometrische, infrarotspektroskopische und NMR-spekstroskopische Daten von Mephedron, Butylon und Methylon sowie einigen ihrer Derivate. Toxichem Krimtech, 1 Jan 2010, 77 (2), 95–116. 380 kB. #1 MS,NMR,IR
Eshleman, AJ; Wolfrum, KM; Hatfield, MG; Johnson, RA; Murphy, KV; Janowsky, A. Substituted methcathinones differ in transporter and receptor interactions. Biochem. Pharmacol., 15 Jun 2013, 85 (12), 1803–1815. 2.2 MB. https://doi.org/10.1016/j.bcp.2013.04.004
Dybdal-Hargreaves, NF; Holder, ND; Ottoson, PE; Sweeney, MD; Williams, T. Mephedrone: Public health risk, mechanisms of action, and behavioral effects. Eur. J. Pharmacol., 15 Aug 2013, 714 (1–3), 32–40. 837 kB. https://doi.org/10.1016/j.ejphar.2013.05.024
Gregg, RA; Rawls, SM. Behavioral pharmacology of designer cathinones: A review of the preclinical literature. Life Sci., 27 Feb 2014, 97 (1), 27–30. 249 kB. https://doi.org/10.1016/j.lfs.2013.10.033
De Felice, LJ; Glennon, RA; Negus, SS. Synthetic cathinones: Chemical phylogeny, physiology, and neuropharmacology. Life Sci., 27 Feb 2014, 97 (1), 20–26. 622 kB. https://doi.org/10.1016/j.lfs.2013.10.029
German, CL; Fleckenstein, AE; Hanson, GR. Bath salts and synthetic cathinones: An emerging designer drug phenomenon. Life Sci., 27 Feb 2014, 97 (1), 2–8. 390 kB. https://doi.org/10.1016/j.lfs.2013.07.023
Angoa-Pérez, M; Kane, MJ; Herrera-Mundo, N; Francescutti, DM; Kuhn, DM. Effects of combined treatment with mephedrone and methamphetamine or 3,4-methylenedioxymethamphetamine on serotonin nerve endings of the hippocampus. Life Sci., 27 Feb 2014, 97 (1), 31–36. 888 kB. https://doi.org/10.1016/j.lfs.2013.07.015
Prosser, JM; Nelson, LS. The toxicology of bath salts: a review of synthetic cathinones. J. Med. Toxicol., 1 Nov 2011, 8 (1), 33–22. 267 kB. https://doi.org/10.1007/s13181-011-0193-z
Iversen, L; Gibbons, S; Treble, R; Setola, V; Huang, X; Roth, BL. Neurochemical profiles of some novel psychoactive substances. Eur. J. Pharmacol., 30 Jan 2013, 700 (1–3), 147–151. 490 kB. https://doi.org/10.1016/j.ejphar.2012.12.006
de Burnaga Sanchez, MJS. Sur un homologue de l’éphédrine. Bull. Soc. Chim. Fr., , 45, 284–286. 600 kB.
McElrath, K; O’Neill, C. Experiences with mephedrone pre- and post-legislative controls: Perceptions of safety and sources of supply. Int. J. Drug Policy, 1 Mar 2011, 22 (2), 120-127. 180 kB. https://doi.org/10.1016/j.drugpo.2010.11.001
Power, JD; Kavanagh, P; McLaughlin, G; O'Brien, J; Talbot, B; Barry, M; Twamley, B; Dowling, G; Brandt, SD. Identification and characterization of an imidazolium by-product formed during the synthesis of 4-methylmethcathinone (mephedrone): Identification and characterization of a mephedrone synthesis imputity. Drug Test. Anal., 1 Oct 2015, 7 (10), 894-902. 1.3 MB. https://doi.org/10.1002/dta.1789
Baumann, MH; Partilla, JS; Lehner, KR; Thorndike, EB; Hoffman, AF; Holy, M; Rothman, RB; Goldberg, SR; Lupica, CR; Sitte, HH; Brandt, SD; Tella, SR; Cozzi, NV; Schindler, CW. Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacol., 1 Mar 2013, 38 (4), 552-562. 1.4 MB. https://doi.org/10.1038/npp.2012.204
Kapitány-Fövény, M; Kertész, M; Winstock, A; Deluca, P; Corazza, O; Farkas, J; Zacher, G; Urbán, R; Demetrovics, Z. Substitutional potential of mephedrone: an analysis of the subjective effects. Hum. Psychopharmacol. Clin. Exp., 1 Jul 2013, 28 (4), 308–316. 141 kB. https://doi.org/10.1002/hup.2297
Bonano, JS; Glennon, RA; Felice, LJ; Banks, ML; Negus, SS. Abuse-related and abuse-limiting effects of methcathinone and the synthetic “bath salts” cathinone analogs methylenedioxypyrovalerone (MDPV), methylone and mephedrone on intracranial self-stimulation in rats. Psychopharmacology, 1 Jan 2014, 231 (1), 199-207. 285 kB. https://doi.org/10.1007/s00213-013-3223-5
Glennon, RA. Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention. Adv. Pharmacol., 1 Jan 2014, 69, 581–620. 564 kB. https://doi.org/10.1016/B978-0-12-420118-7.00015-9
Ogino, M; Naiki, T; Orui, H; Kosone, K; Yamazaki, M. Study of method for identifying phenethylamine drugs. JCCL, 11 Feb 2011, 50, 63-82. 627 kB. Japanese, English abstract LC,MS,NMR,IR
Luethi, D; Kolaczynska, KE; Docci, L; Krähenbühl, S; Hoener, MC; Liechti, ME. Pharmacological profile of mephedrone analogs and related new psychoactive substances. Neuropharmacology, 15 May 2018, 134 (A), 4-12. 1.8 MB. https://doi.org/10.1016/j.neuropharm.2017.07.026 #4-MMC
EMCDDA. New drugs in Europe, 2015, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2016. 1.0 MB.
EMCDDA. New drugs in Europe, 2014, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2015. 879 kB.
EMCDDA. New drugs in Europe, 2013, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2014. 311 kB.
EMCDDA. New drugs in Europe, 2011, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Apr 2012. 401 kB.
EMCDDA. New drugs in Europe, 2010, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2011. 700 kB.
McLaughlin, G; Morris, N; Kavanagh, PV; Power, JD; Dowling, G; Twamley, B; O’Brien, J; Talbot, B; Walther, D; Partilla, JS; Baumann, MH; Brandt, SD. Synthesis, characterization and monoamine transporter activity of the new psychoactive substance mexedrone and its N-methoxy positional isomer, N-methoxymephedrone. Drug Test. Anal., 1 Mar 2017, 9 (3), 358-368. 7.1 MB. https://doi.org/10.1002/dta.2053 #Mephedrone GC,LC,MS,NMR,other
Bonano, JS; Banks, ML; Kolanos, R; Sakloth, F; Barnier, ML; Glennon, RA; Cozzi, NV; Partilla, JS; Baumann, MH; Negus, SS. Quantitative structure-activity relationship analysis of the pharmacology of para-substituted methcathinone analogues: QSAR of para-substituted methcathinone analogues. Br. J. Pharmacol., 1 May 2015, 172 (10), 2433-2444. 985 kB. https://doi.org/10.1111/bph.13030 #4-CH3 MCAT
Leffler, AM; Smith, PB; de Armas, A; Dorman, FL. The analytical investigation of synthetic street drugs containing cathinone analogs. Forensic Sci. Int., 1 Jan 2014, 234, 50-56. 973 kB. https://doi.org/10.1016/j.forsciint.2013.08.021
Gwak, S; Arroyo-Mora, LE; Almirall, JR. Qualitative analysis of seized synthetic cannabinoids and synthetic cathinones by gas chromatography triple quadrupole tandem mass spectrometry. Drug Test. Anal., 1 Feb 2015, 7 (2), 121-130. 1.1 MB. https://doi.org/10.1002/dta.1667 #2
Meyer, MR; Wilhelm, J; Peters, FT; Maurer, HH. β-Keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal. Bioanal. Chem., 1 Jun 2010, 397 (3), 1225–1233. 451 kB. https://doi.org/10.1007/s00216-010-3636-5 GC,MS
Collins, M. Some new psychoactive substances: Precursor chemical and synthesis-driver end-products. Drug Test. Anal., 1 Jul 2001, 3 (7–8), 404–416. 178 kB. https://doi.org/10.1002/dta.315
Burns, L; Roxburgh, A; Matthews, A; Bruno, R; Lenton, S; Van Buskirk, J. The rise of new psychoactive substance use in Australia. Drug Test. Anal., 1 Jul 2014, 6 (7-8), 846-849. 422 kB. https://doi.org/10.1002/dta.1626
Burns, L; Roxburgh, A; Bruno, R; Van Buskirk, J. Monitoring drug markets in the Internet age and the evolution of drug monitoring systems in Australia. Drug Test. Anal., 1 Jul 2014, 6 (7-8), 840-845. 113 kB. https://doi.org/10.1002/dta.1613
Vidal Giné, C; Espinosa, IF; Vilamala, MV. New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon? Drug Test. Anal., 1 Jul 2014, 6 (7-8), 819-824. 113 kB. https://doi.org/10.1002/dta.1610
Kavanagh, PV; Power, JD. New psychoactive substances legislation in Ireland – Perspectives from academia. Drug Test. Anal., 1 Jul 2014, 6 (7-8), 884-891. 1.2 MB. https://doi.org/10.1002/dta.1598
Fornal, E. Study of collision-induced dissociation of electrospray-generated protonated cathinones. Drug Test. Anal., 1 Jul 2014, 6 (7-8), 705-715. 527 kB. https://doi.org/10.1002/dta.1573 #5
Rojek, S; Kłys, M; Maciów-Głąb, M; Kula, K; Strona, M. Cathinones derivatives-related deaths as exemplified by two fatal cases involving methcathinone with 4-methylmethcathinone and 4-methylethcathinone. Drug Test. Anal., 1 Jul 2014, 6 (7-8), 770-777. 444 kB. https://doi.org/10.1002/dta.1615
Calderon, SN; Klein, M. A regulatory perspective on the abuse potential evaluation of novel stimulant drugs in the United States. Neuropharmacology, 1 Dec 2014, 87, 97-103. 266 kB. https://doi.org/10.1016/j.neuropharm.2014.04.001
Forsyth, AJM. Virtually a drug scare: Mephedrone and the impact of the Internet on drug news transmission. Int. J. Drug Policy, 1 May 2012, 23 (3), 198-209. 788 kB. https://doi.org/10.1016/j.drugpo.2011.12.003
Terry, SM. Bath Salt Abuse: More Than Just Hot Water. J. Emerg. Nurs., 1 Jan 2014, 40 (1), 88-91. 128 kB. https://doi.org/10.1016/j.jen.2013.05.013
Griffiths, P; Evans-Brown, M; Sedefov, R. Getting up to speed with the public health and regulatory challenges posed by new psychoactive substances in the information age: Editorial. Addiction, 1 Jan 2013, 108 (10), 1700-1703. 93 kB. https://doi.org/10.1111/add.12287
Jebadurai, J; Schifano, F; Deluca, P. Recreational use of 1-(2-naphthyl)-2-(1-pyrrolidinyl)-1-pentanone hydrochloride (NRG-1), 6-(2-aminopropyl) benzofuran (Benzofury/6-APB) and NRG-2 with review of available evidence-based literature. Hum. Psychopharmacol. Clin. Exp., 1 Jul 2013, 28 (4), 356–364. 612 kB. https://doi.org/10.1002/hup.2302
Pedersen, AJ; Reitzel, LA; Johansen, SS; Linnet, K. In vitro metabolism studies on mephedrone and analysis of forensic cases. Drug Test. Anal., 1 Jun 2013, 5 (6), 430-438. 378 kB. https://doi.org/10.1002/dta.1369
Mas-Morey, P; Visser, MHM; Winkelmolen, L; Touw, DJ. Clinical Toxicology and Management of Intoxications With Synthetic Cathinones ("Bath Salts"). J. Pharm. Pract., 25 Nov 2012, 26 (4), 353-357. 312 kB. https://doi.org/10.1177/0897190012465949
Nycz, JE; Malecki, G; Zawiazalec, M; Pazdziorek, T. X-ray structures and computational studies of several cathinones. J. Mol. Struct., 14 Sep 2011, 1002 (1), 10–18. 1.1 MB. https://doi.org/10.1016/j.molstruc.2011.06.030 #1d NMR,IR,other
Adamowicz, P; Zuba, D. Discrimination among designer drug isomers by chromatographic and spectrometric methods. In Chromatographic Techniques in the Forensic Analysis of Designer Drugs; Kowalska, T; Sajewicz, M; Sherma, J, Eds., CRC Press, Taylor & Francis Group, 1 Jan 2018; pp 211–232. 1.1 MB.
Maurer, HH. Chemistry, pharmacology, and metabolism of emerging drugs of abuse. Ther. Drug Monit., 1 Oct 2010, 32 (5), 544–549. 142 kB. https://doi.org/10.1097/FTD.0b013e3181eea318 #Mephedrone
Grumann, C; Auwärter, V. Separation of positional isomers of nine 2-phenethylamine-derived designer drugs by liquid chromatography-tandem mass spectrometry. Drug Test. Anal., 1 Jul 2018, 10 (7), 1184–1191. 861 kB. https://doi.org/10.1002/dta.2371 #4-MMC LC,MS
Gaspar, H; Bronze, S; Oliveira, C; Victor, BL; Machuqueiro, M; Pacheco, R; Caldeira, MJ; Santos, S. Proactive response to tackle the threat of emerging drugs: Synthesis and toxicity evaluation of new cathinones. Forensic Sci. Int., 1 Sep 2018, 290, 146–156. 1.6 MB. https://doi.org/10.1016/j.forsciint.2018.07.001 #Mephedrone MS,NMR
Gibbons, S; Zloh, M. An analysis of the ‘legal high’ mephedrone. Bioorg. Med. Chem. Lett., 1 Jul 2010, 20 (14), 4135–4139. 1.2 MB. https://doi.org/10.1016/j.bmcl.2010.05.065 #Mephedrone MS,NMR,other
Saha, K; Partilla, JS; Lehner, KR; Seddik, A; Stockner, T; Holy, M; Sandtner, W; Ecker, GF; Sitte, HH; Baumann, MH. ‘Second-generation’ mephedrone analogs, 4-MEC and 4-MePPP, differentially affect monoamine transporter function. Neuropsychopharmacol., 1 May 2015, 40 (6), 1321–1331. 738 kB. https://doi.org/10.1038/npp.2014.325 #Mephedrone
EMCDDA. New drugs in Europe, 2008, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2009. 265 kB. #3
Yoshida, M; Suzuki, J; Takahashi, M; Moriyasu, T; Nakajima, J; Kanai, C; Nagashima, M; Seto, T; Shimizu, M; Hamano, T; Nakae, D. Investigations of designated substances detected from April 2010 to March 2011. Ann. Rep. Tokyo Metr. Inst. P. H., 1 Jan 2011, 62 107–114. 790 kB. #4-MMC GC,LC,MS,UV
Suzuki, J; Moriyasu, T; Nagashima, M; Kanai, C; Shimizu, M; Hamano, T; Nagayama, T. Analysis of uncontrolled drugs purchased in the fiscal year 2009. Ann. Rep. Tokyo Metr. Inst. P. H., 1 Jan 2010, 61 163–172. 971 kB. #4-Methylmethcathinone LC,MS,NMR
Chapman, SJ. Novel Psychoactive Spectra: NMR of (mostly) Novel Psychoactive Substances. BLOTTER, 25 Jun 2018, 3 (2). https://doi.org/10.16889/isomerdesign-6 #Mephedrone NMR
Johnson, MW; Griffiths, RR; Hendricks, PS; Henningfield, JE. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 1 Nov 2018, 142, 143-166. 2.5 MB. https://doi.org/10.1016/j.neuropharm.2018.05.012 #Mephedrone
Kavanaugh, PR; Biggers, Z. Competing constructions of bath salts use and risk of harm in two mediated contexts. Crime Media Cult., 1 Aug 2019, 15 (2), 217-237. 774 kB. https://doi.org/10.1177/1741659018763863 #Mephedrone
Ferreira, B; da Silva, DD; Carvalho, F; de Lourdes Bastos, M; Carmo, H. The novel psychoactive substance 3-methylmethcathinone (3-MMC or metaphedrone): A review. Forensic Sci. Int., 1 Feb 2019, 295, 54–63. 624 kB. https://doi.org/10.1016/j.forsciint.2018.11.024 #4-MMC
Simmons, SJ; Leyrer-Jackson, JM; Oliver, CF; Hicks, C; Muschamp, JW; Rawls, SM; Olive, MF. DARK classics in chemical neuroscience: Cathinone-derived psychostimulants. ACS Chem. Neurosci., 17 Oct 2018, 9 (10), 2379–2394. 1.6 MB. https://doi.org/10.1021/acschemneuro.8b00147 #Mephedrone (4-MMC)
Rickli, A; Hoener, MC; Liechti, ME. Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones. Eur. Neuropsychopharmacol., 1 Mar 2015, 25 (3), 365–376. 1.6 MB. https://doi.org/10.1016/j.euroneuro.2014.12.012 #4-Methylmethcathinone
Mayer, FP; Cintulova, D; Pittrich, DA; Wimmer, L; Luethi, D; Holy, M; Jaentsch, K; Tischberger, S; Gmeiner, G; Hoener, MC; Liechti, ME; Mihovilovic, MD; Sitte, HH. Stereochemistry of phase-1 metabolites of mephedrone determines their effectiveness as releasers at the serotonin transporter. Neuropharmacology, 1 Apr 2019, 148, 199-209. 1.4 MB. https://doi.org/10.1016/j.neuropharm.2018.12.032 #Mephedrone
Anon. Separation and identification of methyl-methcathinones. Hungarian Institute for Forensic Sciences, 11 Mar 2011. 529 kB. #4-MMC GC,LC,MS,IR,UV,TLC
Baumann, MH; Walters, HM; Niello, M; Sitte, HH. Neuropharmacology of synthetic cathinones. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 113–142. 409 kB. https://doi.org/10.1007/164_2018_178 #Mephedrone
Luethi, D; Liechti, ME. Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics. Int. J. Neuropsychoph., 1 Oct 2018, 21 (10), 926–931. 254 kB. https://doi.org/10.1093/ijnp/pyy047 #S1 Cathinones Mephedrone
Kronstrand, R; Guerrieri, D; Vikingsson, S; Wohlfarth, A; Gréen, H. Fatal poisonings associated with new psychoactive substances. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 495–541. 477 kB. https://doi.org/10.1007/164_2018_110 #Mephedrone
Kraemer, M; Boehmer, A; Madea, B; Maas, A. Death cases involving certain new psychoactive substances: A review of the literature. Forensic Sci. Int., 1 May 2019, 298, 186–267. 6.7 MB. https://doi.org/10.1016/j.forsciint.2019.02.021 #Mephedrone
Walther, D; Shalabi, AR; Baumann, MH; Glennon, RA. Systematic structure–activity studies on selected 2-, 3-, and 4-monosubstituted synthetic methcathinone analogs as monoamine transporter releasing agents. ACS Chem. Neurosci., 16 Jan 2019, 10 (1), 740–745. 498 kB. https://doi.org/10.1021/acschemneuro.8b00524 #4c NMR,other
Bork, W; Dahlenburg, R; Gimbel, M; Jacobsen-Bauer, A; Zörntlein, S. Herleitung Von Grenzwerten Der „nicht Geringen Menge“ Im Sinne Des Btmg. Toxichem Krimtech, 1 Jan 2019, 86 (1), 5–91. 4.4 MB. #CA-021
Nishimura, Y; Tanaka, S; Ikeda, H; Yamazaki, Y. Study of method for identifying regioisomers of controlled drugs. JCCL, 1 Dec 2015, (55), 65–85. 707 kB. #4-MMC Japanese, English abstract GC,MS,UV
Kolanos, R; Solis, E; Sakloth, F; De Felice, LJ; Glennon, RA. “Deconstruction” of the abused synthetic cathinone methylenedioxypyrovalerone (MDPV) and an examination of effects at the human dopamine transporter. ACS Chem. Neurosci., 18 Dec 2013, 4 (12), 1524–1529. 393 kB. https://doi.org/10.1021/cn4001236 #5 NMR,other
Anneken, JH; Angoa-Perez, M; Sati, GC; Crich, D; Kuhn, DM. Assessing the role of dopamine in the differential neurotoxicity patterns of methamphetamine, mephedrone, methcathinone and 4-methylmethamphetamine. Neuropharmacology, 1 May 2018, 134, 46–56. 3.5 MB. https://doi.org/10.1016/j.neuropharm.2017.08.033 #MEPH
Meyers-Riggs, B. AIRCR jumps the shark. countyourculture, countyourculture: rational exploration of the underground, 30 Dec 2010.
Hägele, JS; Basrak, M; Schmid, MG. Enantioselective separation of novel psychoactive substances using a Lux® AMP 3 μm column and HPLC-UV. J. Pharm. Biomed. Anal., 5 Feb 2020, 179, 112967. 3.6 MB. https://doi.org/10.1016/j.jpba.2019.112967 #P1; P27 LC
Clancy, L; Philp, M; Shimmon, R; Fu, S. Development and validation of a color spot test method for the presumptive detection of 25-NBOMe compounds. Drug Test. Anal., 19 Aug 2020, 13 (5), 929-943. 11.3 MB. https://doi.org/10.1002/dta.2905 #4-methylmethcathinone
Alotaibi, MR; Husbands, SM; Blagbrough, IS. 1H, 13C, 15N HMBC, and 19F NMR spectroscopic characterisation of seized flephedrone, cut with benzocaine. J. Pharm. Biomed. Anal., 25 Mar 2015, 107, 535–538. 588 kB. https://doi.org/10.1016/j.jpba.2014.12.033 #Mephedrone GC,NMR
Åstrand, A; Guerrieri, D; Vikingsson, S; Kronstrand, R; Green, H. In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT1A, and 5-HT2A receptors—On-target receptor potency and efficacy, and off-target effects. Forensic Sci. Int., 1 Dec 2020, 317, 110553. 1.7 MB. https://doi.org/10.1016/j.forsciint.2020.110553 #Mephedrone
Rouxinol, D; Carmo, H; Carvalho, F; de Lourdes Bastos, M; da Silva, DD. Pharmacokinetics, pharmacodynamics, and toxicity of the new psychoactive substance 3,4-dimethylmethcathinone (3,4-DMMC). Forensic Toxicol., 1 Jan 2020, 38 (1), 15–29. 1.3 MB. https://doi.org/10.1007/s11419-019-00494-x #4-MMC
Toole, KE; Fu, S; Shimmon, RG; Taflaga, S. The use of a portable attenuated total reflectance-Fourier transform infrared spectrometer for the preliminary identification of methcathinone and analogues of methcathinone. JCLIC, 1 Jan 2012, 22 (1-2), 11-24. 1.5 MB. IR
Combs, MR. Analytical profile of 4-methylmethcathinone. JCLIC, 1 Jan 2010, 20 (1), 2-4. 186 kB. GC,MS,IR
Hulme, MC; Hayatbakhsh, A; Brignall, RM; Gilbert, N; Costello, A; Schofield, CJ; Williamson, DC; Kemsley, EK; Sutcliffe, OB; Mewis, RE. Detection, discrimination and quantification of amphetamine, cathinone and nor-ephedrine regioisomers using benchtop 1H and 19F nuclear magnetic resonance spectroscopy. Magn. Reson. Chem., 20 Apr 2021, n/a. 1.9 MB. https://doi.org/10.1002/mrc.5156 #2c GC,MS,NMR,IR,TLC
Antonides, LH; Brignall, RM; Costello, A; Ellison, J; Firth, SE; Gilbert, N; Groom, BJ; Hudson, SJ; Hulme, MC; Marron, J; Pullen, ZA; Robertson, TBR; Schofield, CJ; Williamson, DC; Kemsley, EK; Sutcliffe, OB; Mewis, RE. Rapid identification of novel psychoactive and other controlled substances using low-field 1H NMR spectroscopy. ACS Omega, 30 Apr 2019, 4 (4), 7103–7112. 1.3 MB. https://doi.org/10.1021/acsomega.9b00302 #Mephedrone NMR
Philp, M; Shimmon, R; Stojanovska, N; Tahtouh, M; Fu, S. Development and validation of a presumptive colour spot test method for the detection of piperazine analogues in seized illicit materials. Anal. Methods, 1 Jan 2013, 5 (20), 5402. 783 kB. https://doi.org/10.1039/c3ay40511g #4-Methylmethcathinone (4-MMC) MS,NMR,IR,spot
Bovens, M; Schläpfer, M. A survey of recent seizures and an attempt to a more effective handling from a Swiss perspective. Toxichem Krimtech, 1 Apr 2011, 78 (SI), 167–175. 708 kB. #11
Nutt, D. Perverse effects of the precautionary principle: how banning mephedrone has unexpected implications for pharmaceutical discovery. Ther. Adv. Psychopharmacol., 1 Apr 2011, 1 (2), 35–36. 63 kB. https://doi.org/10.1177/2045125311406958 #Mephedrone
van Hout, MC; Brennan, R. ‘Heads held high’: An exploratory study of legal highs in pre-legislation Ireland. J. Ethn. Subst. Abuse, 2 Sep 2011, 10 (3), 256–272. 97 kB. https://doi.org/10.1080/15332640.2011.600210